Delving into the Latest Updates on QX-013N with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

QX013N

Target

c-Kit

Action

inhibitors

Mechanism

c-Kit inhibitors(Stem cell growth factor receptor inhibitors)

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal Diseases

Active Indication

Chronic Urticaria

Inactive Indication-

Originator Organization

Qyuns Therapeutics Co., Ltd.Startup

Active Organization

Qyuns Therapeutics Co., Ltd.Startup

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要研究目的：评价QX013N 单次给药在健康人体的安全性和耐受性。次要研究目的：评价QX013N 单次给药在健康人体的药代动力学（PK）特征，以及皮下给药与静脉给药相比下的绝对生物利用度；评价QX013N单次给药在健康人体的免疫原性特征。

[Translation]

Primary study objectives: To evaluate the safety and tolerability of a single dose of QX013N in healthy humans. Secondary study objectives: To evaluate the pharmacokinetic (PK) characteristics of a single dose of QX013N in healthy humans, as well as the absolute bioavailability of subcutaneous administration compared with intravenous administration; to evaluate the immunogenicity characteristics of a single dose of QX013N in healthy humans.

Start Date14 Jun 2024

Sponsor / Collaborator

Qyuns Therapeutics Co., Ltd.Startup

ChiCTR2400085021

/ SuspendedPhase 1IIT

A Single-center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics of QX013N Injection in Healthy Adult Subjects

Start Date01 Jun 2024

Sponsor / Collaborator-

100 Clinical Results associated with QX-013N

Login to view more data

100 Translational Medicine associated with QX-013N

Login to view more data

100 Patents (Medical) associated with QX-013N

Login to view more data

100 Deals associated with QX-013N

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Urticaria	Phase 1	China	Qyuns Therapeutics Co., Ltd.Startup	14 Jun 2024

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data